Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

European Journal of Cancer

Volumn 48, Issue 16, 2012, Pages 3082-3092

  Lipton, Allan ^a   Fizazi, Karim ^b   Stopeck, Alison T ^c   Henry, David H ^d   Brown, Janet E ^e   Yardley, Denise A ^f   Richardson, Gary E ^g   Siena, Salvatore ^h   Maroto, Pablo ⁱ   Clemens, Michael ^j   Bilynskyy, Boris ^k   Charu, Veena ^l   Beuzeboc, Philippe ^m   Rader, Michael ⁿ   Viniegra, Maria ^o   Saad, Fred ^p   Ke, Chunlei ^q   Braun, Ada ^q   Jun, Susie ^q  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF ARIZONA   (United States)

^d PENNSYLVANIA HOSPITAL   (United States)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

^g CABRINI HOSPITAL   (Australia)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j Klinikum Mutterhaus der Borromaeerinnen   (Germany)

^k Cancer Treatment and Diagnostic Center   (Ukraine)

^l Pacific Cancer Medical Center Inc   (United States)

^m INSTITUT CURIE   (France)

ⁿ Nyack Hospital   (United States)

^o Corporacion Medica de General San Martin ^*  (Argentina)

^p CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^q AMGEN INC   (United States)

more..

Author keywords

Bone metastasis; Denosumab; Skeletal related events; Zoledronic acid

Indexed keywords

DENOSUMAB; PLACEBO; ZOLEDRONIC ACID;

ADULT; ANEMIA; ARTICLE; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; SPINAL CORD COMPRESSION; STATISTICAL SIGNIFICANCE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOCALCEMIA; IMIDAZOLES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867582660     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.08.002     Document Type: Article

References (36)

1. R.E. Coleman, A. Lipton, and G.D. Roodman Metastasis and bone loss: advancing treatment and prevention Cancer Treat Rev 36 8 2010 615 620
2. R.E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 20 Pt. 2 2006 6243s 6249s
3. M. Norgaard, A.O. Jensen, and J.B. Jacobsen Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007) J Urol 184 1 2010 162 167
4. T. Delea, C. Langer, and J. McKiernan The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer Oncology 67 5-6 2004 390 396
5. L. Costa, X. Badia, E. Chow, A. Lipton, and A. Wardley Impact of skeletal complications on patients' quality of life, mobility, and functional independence Support Care Cancer 16 8 2008 879 889
6. M.J. Lage, B.L. Barber, D.J. Harrison, and S. Jun The cost of treating skeletal-related events in patients with prostate cancer Am J Manag Care 14 5 2008 317 322
7. A. Barlev, X. Song, B. Ivanov, V. Setty, and K. Chung Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer J Manag Care Pharm 16 9 2010 693 702
8. G.N. Hortobagyi, R.L. Theriault, and A. Lipton Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group J Clin Oncol 16 6 1998 2038 2044
9. R.L. Theriault, A. Lipton, and G.N. Hortobagyi Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group J Clin Oncol 17 3 1999 846 854
10. L.S. Rosen, D. Gordon, and M. Kaminski Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial Cancer J 7 5 2001 377 387
11. F. Saad, D.M. Gleason, and R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 19 2002 1458 1468
12. L.S. Rosen, D. Gordon, and S. Tchekmedyian Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 16 2003 3150 3157
13. Zometa (zoledronic acid) injection, concentrate for intravenous infusion [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
14. V. Launay-Vacher, S. Oudard, and N. Janus Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study Cancer 110 6 2007 1376 1384
15. D.L. Lacey, E. Timms, and H.L. Tan Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 2 1998 165 176
16. H. Yasuda, N. Shima, and N. Nakagawa Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 3 1998 1329 1337
17. K. Fizazi, J. Yang, and S. Peleg Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts Clin Cancer Res 9 7 2003 2587 2597
18. C. Van Poznak, S.S. Cross, and M. Saggese Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours J Clin Pathol 59 1 2006 56 63
19. U. Heider, C. Langelotz, and C. Jakob Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma Clin Cancer Res 9 4 2003 1436 1440
20. J.R. Canon, M. Roudier, and R. Bryant Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis Clin Exp Metastasis 25 2 2008 119 129
21. A. Lipton, G.G. Steger, and J. Figueroa Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol 25 28 2007 4431 4437
22. G.K. Ellis, H.G. Bone, and R. Chlebowski Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 30 2008 4875 4882
23. K. Fizazi, A. Lipton, and X. Mariette Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 10 2009 1564 1571
24. M.R. Smith, B. Egerdie, and N. Hernandez Toriz Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 8 2009 745 755
25. A.T. Stopeck, A. Lipton, and J.J. Body Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 35 2010 5132 5139
26. K. Fizazi, M. Carducci, and M. Smith A randomised, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in men with castration-resistant prostate cancer Lancet 377 2011 813 822
27. D.H. Henry, L. Costa, and F. Goldwasser A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 9 2011 1125 1132
28. XGEVA (denosumab) injection, for subcutaneous use, [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2012.
29. F. Saad, J.E. Brown, and C. Van Poznak Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Ann Oncol 23 5 2012 1341 1347
30. J.L. Abrahm, M.B. Banffy, and M.B. Harris Spinal cord compression in patients with advanced metastatic cancer: "all I care about is walking and living my life" JAMA 299 8 2008 937 946
31. C. Clare, D. Royle, and K. Saharia Painful bone metastases: a prospective observational cohort study Palliat Med 19 7 2005 521 525
32. R.E. Coleman Management of bone metastases Oncologist 5 6 2000 463 470
33. A. Stopeck, M. Rader, and D. Henry Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States J Med Econ 15 4 2012 712 723
34. V. Launay-Vacher, J. Ayllon, and N. Janus Drug management of prostate cancer: prevalence and consequences of renal insufficiency Clin Genitourin Cancer 7 3 2009 E83 E89
35. W.K. Oh, K. Proctor, and M. Nakabayashi The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid Cancer 109 6 2007 1090 1096
36. M. Cozzolino, P. Ciceri, E.M. Volpi, L. Olivi, and P.G. Messa Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease Blood Purif 27 4 2009 338 344